Subscribe To
DCGO / DocGo: Can Sustain Rapid, Profitable Expansion
DCGO News
By The Motley Fool
September 18, 2023
Why DocGo Stock Plummeted by 7% on Monday
Its CEO resigned abruptly. His official bio stated falsely that he earned a master's degree in artificial intelligence (AI). more_horizontal
By Zacks Investment Research
September 15, 2023
DocGo Inc. (DCGO) Moves 6.8% Higher: Will This Strength Last?
DocGo Inc. (DCGO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the s more_horizontal
By Seeking Alpha
September 11, 2023
DocGo: Preventing Onboarding Problem From Turning Into A Crisis (Rating Downgrade)
DocGo was rewarded a no-bid contract by the NYC to provide medical care for the migrants, but this large contract is facing the risk of being revoked more_horizontal
By The Motley Fool
September 6, 2023
Why Shares of DocGo Are Slumping Wednesday
DocGo improved revenue in the second quarter. The company has added major contracts this year with EmblemHealth and Carnival Cruise Lines. more_horizontal
By Seeking Alpha
August 7, 2023
DocGo Inc. (DCGO) Q2 2023 Earnings Call Transcript
DocGo Inc. (NASDAQ:DCGO ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Corporate Participants Mike Cole - Director-Investor Relations An more_horizontal
By Zacks Investment Research
August 7, 2023
DocGo Inc. (DCGO) Reports Q2 Loss, Tops Revenue Estimates
DocGo Inc. (DCGO) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.07 p more_horizontal
By Zacks Investment Research
June 22, 2023
DocGo Inc. (DCGO) Surges 5.0%: Is This an Indication of Further Gains?
DocGo Inc. (DCGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for th more_horizontal
By Proactive Investors
May 12, 2023
DocGo's growth story keeps building, analysts say after mixed 1Q results
DocGo delivered what analysts at Canaccord called “mixed” results, but that was enough for the firm to reiterate its Buy rating and $13 price targ more_horizontal